Evidence map›Paper›PMID 40918456›Full record

ReviewOncology research2025

Combining Chemotherapeutic Agents, Targeted Therapies, Vaccines and Natural Bioactive Compounds for Mesothelioma: Advances and Perspectives.

Raffaele Carrano, Carlotta Zucca, Nicla Cristina, Martina Grande, Eleonora Leti Maggio, Riccardo Bei, Antonio Infante, Chiara Focaccetti, Valeria Lucarini, Loredana Cifaldi and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Raffaele CarranoDepartment of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", Rome, 00133, Italy.
Carlotta ZuccaDepartment of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", Rome, 00133, Italy.
Nicla CristinaDepartment of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", Rome, 00133, Italy.
Martina GrandeDepartment of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", Rome, 00133, Italy.
Eleonora Leti MaggioDepartment of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", Rome, 00133, Italy.
Riccardo BeiMedical School, University of Rome "Tor Vergata", Rome, 00133, Italy.
Antonio InfanteMedical School, University of Rome "Tor Vergata", Rome, 00133, Italy.
Chiara FocaccettiDepartment of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", Rome, 00133, Italy.
Valeria LucariniDepartment of Life, Health and Health Profession Sciences, Link Campus University, Rome, 00165, Italy.
Loredana CifaldiDepartment of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", Rome, 00133, Italy.
Laura MasuelliDepartment of Experimental Medicine, University of Rome "Sapienza", Rome, 00161, Italy.
Luciano MuttiDepartment of Applied Sciences and Biotechnology, Università dell'Aquila, L'Aquila, 67100, Italy.
Camilla PalumboDepartment of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", Rome, 00133, Italy.
Monica BenvenutoDepartment of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", Rome, 00133, Italy.
Roberto BeiDepartment of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", Rome, 00133, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesothelioma is a rare and aggressive cancer with a poor prognosis and limited therapeutic options. Despite recent advances, conventional treatment approaches remain largely ineffective due to late diagnosis, chemoresistance and immunosuppressive tumor microenvironment. This review reports the latest studies on combination therapies for mesothelioma, focusing on the potential of integrating chemotherapeutic agents, molecularly targeted agents, vaccines and natural bioactive compounds such as polyphenols. Clinical and preclinical studies demonstrate that integrating immune-modulating drugs or molecular inhibitors with chemotherapy can improve survival and reduce tumor progression in mesothelioma models and patients. Vaccine-based strategies show potential for inducing host-persistent immune responses when combined with conventional treatments. Moreover, natural compounds such as polyphenols show synergistic effects with chemotherapeutics and targeted agents by modulating several signaling pathways involved in cancer cell growth and progression and by overcoming drug resistance. While several combination strategies are under clinical investigation, further studies are needed to develop more effective and personalized therapeutic approaches that could be translated into standardized treatment protocols.

Indexed as

Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBiological ProductsCancer VaccinesMesotheliomaMolecular Targeted TherapyAnimalsCombined Modality TherapyHumansTumor MicroenvironmentAntineoplastic AgentsBiological ProductsCancer Vaccinesanticancer vaccineschemotherapyMesotheliomapolyphenolstargeted therapy

Identifiers

PMID40918456
PMCPMC12408854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.